IBD 📈 Northern Lights Fund Trust - Overview
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US1416376036 • Corporate Bond
IBD: Corporate Bonds, Investment Grade Securities
The fund generally invests at least 80% of its total assets in the component securities of the index. The index Provider selects domestic corporate bonds issued by companies that are considered large capitalization companies, are rated investment grade quality from a bond ratings agency widely recognized in the financial services industry and which have an Inspire Impact Score of zero or higher. ‣ Company URL: ‣ Domicile:
Additional Sources for IBD ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
IBD ETF Overview
| Market Cap in USD | 332m |
| Category | Corporate Bond |
| TER | 0.44% |
| IPO / Inception | 2017-07-10 |
IBD ETF Ratings
| Growth 5y | 5.21% |
| Fundamental | - |
| Dividend | 58.6% |
| Rel. Strength Industry | 152 |
| Analysts | - |
| Fair Price Momentum | 22.53 USD |
| Fair Price DCF | - |
IBD Dividends
| Dividend Yield 12m | 3.67% |
| Yield on Cost 5y | 3.79% |
| Annual Growth 5y | 3.45% |
| Payout Consistency | 92.2% |
IBD Growth Ratios
| Growth Correlation 3m | -18.8% |
| Growth Correlation 12m | 84.1% |
| Growth Correlation 5y | -31.8% |
| CAGR 5y | 0.62% |
| CAGR/Mean DD 5y | 0.12 |
| Sharpe Ratio 12m | -0.17 |
| Alpha | -6.67 |
| Beta | 0.24 |
| Volatility | 5.43% |
| Current Volume | 19k |
| Average Volume 20d | 52k |
What is the price of IBD stocks?
As of December 27, 2024, the stock is trading at USD 23.48 with a total of 18,980 shares traded.
Over the past week, the price has changed by +0.26%, over one month by -0.18%, over three months by -1.22% and over the past year by +3.85%.
As of December 27, 2024, the stock is trading at USD 23.48 with a total of 18,980 shares traded.
Over the past week, the price has changed by +0.26%, over one month by -0.18%, over three months by -1.22% and over the past year by +3.85%.
Is Northern Lights Fund Trust a good stock to buy?
Neither. Based on ValueRay Analyses, Northern Lights Fund Trust is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 5.21 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of IBD as of December 2024 is 22.53. This means that IBD is currently overvalued and has a potential downside of -4.05%.
Neither. Based on ValueRay Analyses, Northern Lights Fund Trust is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 5.21 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of IBD as of December 2024 is 22.53. This means that IBD is currently overvalued and has a potential downside of -4.05%.
Is IBD a buy, sell or hold?
Northern Lights Fund Trust has no consensus analysts rating.
Northern Lights Fund Trust has no consensus analysts rating.
What are the forecast for IBD stock price target?
According to ValueRays Forecast Model, IBD Northern Lights Fund Trust will be worth about 24.5 in December 2025. The stock is currently trading at 23.48. This means that the stock has a potential upside of +4.17%.
According to ValueRays Forecast Model, IBD Northern Lights Fund Trust will be worth about 24.5 in December 2025. The stock is currently trading at 23.48. This means that the stock has a potential upside of +4.17%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 24.5 | 4.2% |